Aimmune statement on ICER final report on AR101 for peanut allergy

11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...

Read more →

ICER publishes evidence report on treatments for Duchenne muscular dystrophy

11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...

Read more →

ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks

10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...

Read more →

Institute for Clinical and Economic Review lists potential topics for assessments in 2020

9 July 2019 - The Institute for Clinical and Economic Review has released its preliminary list of potential assessment topics ...

Read more →

ICER posts draft scoping document for the assessment of treatments for acute migraine

28 June 2019 - Document open to public comment until 19 July 2019 ...

Read more →

It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...

Read more →

U.S. group says Novartis MS drug price out of line with benefit

21 June 2019 - A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new ...

Read more →

Novel approaches to value assessment within the cost-effectiveness framework

20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...

Read more →

ICER issues final report and policy recommendations on esketamine for treatment-resistant depression

20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, ...

Read more →

Institute for Clinical and Economic Review issues final report and policy recommendations on siponimod for secondary progressive multiple sclerosis

20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate siponimod offers superior effectiveness for patients ...

Read more →

Boston drug pricing watchdog group has pharma companies’ attention

19 June 2019 - His adversaries call him a shill for health insurers, a bloodless bean counter who would rather ...

Read more →

Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price

18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...

Read more →

Asthma and Allergy Foundation of America elevates patient voice in ICER review of new peanut allergy treatments

14 June 2019 - On June 11 in Oakland, CA the Institute for Clinical and Economic Review and its California Technology ...

Read more →

New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?

12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...

Read more →

Aimmune wins over ICER for peanut allergy product

12 June 2019 - Analysts predict blockbuster status for first-in-class. ...

Read more →